Bibliography
- Brooks PM. Impact of osteoarthritis on individuals and society: how much disability? Social consequences and health economic implications. Curr Opin Rheumatol 2002;14:573-7
- Wollheim FA. Current pharmacological treatment of osteoarthritis. Drugs 1996;52:27-38
- McAlindon T. Glusoamine for osteoarthritis: dawn of a new era? Lancet 2001;357:247-8
- Chard J, Dieppe P. Glucosamine for osteoarthritis: magic, hype, or confusion? BMJ 2001;322:1439-40
- Reginster JY, Deroisy R, Rovati LC, Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001;357:251-6
- Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4
- Murphy G, Nagase H. Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair? Nat Clin Pract Rheumatol 2008;4:128-35
- Li NG, Shi ZH, Tang YP, Duan JA. Selective matrix metalloproteinase inhibitors for cancer. Curr Med Chem 2009;16:3805-27
- Johnson AR, Pavlovsky AG, Ortwine DF, Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 2007;282:27781-91
- Billinghurst RC, Dahlberg L, Ionescu M, Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest 1997;99:1534-45
- Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-92
- Levitt NC, Eskens FALM, O'Byrne KJ, Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer. Clin Cancer Res 2001;7:1912-22
- Li NG, Shi ZH, Tang YP, New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem 2011;18:977-1001
- Li W, Hua Y, Li J, 3,4-Disubstituted benzofuran P1' MMP-13 inhibitors: optimization of selectivity and reduction of protein binding. Bioorg Med Chem Lett 2009;19:4546-50
- Kolodziej SA, Hockerman SL, DeCrescenzo GA, MMP-13 selective isonipecotamide alpha-sulfone hydroxamates. Bioorg Med Chem Lett 2010;20:3561-4
- Gao DA, Xiong Z, Heim-Riether A, SAR studies of non-zinc-chelating MMP-13 inhibitors: Improving selectivity and metabolic stability. Bioorg Med Chem Lett 2010;20:5039-43
- Savi CD, Morley AD, Nash I, Lead optimisation of selective non-zinc binding inhibitors of MMP13. Part 2. Bioorg Med Chem Lett 2012;22:271-7
- Blagg JA, Noe MC, Wolf-Gouveia LA, Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14. Bioorg Med Chem Lett 2005;15:1807-10
- McGeehan GM, Becherer JD, Bast RC, Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994;370:558-61
- Peschon JJ, Slack JL, Reddy P, An essential role for ectodomain shedding in mammalian development. Science 1998;282:1281-4
- Gallea-Robache S, Morand V, Millet S, A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells. Cytokine 1997;9:340-6
- Hooper NM, Kariran EH, Turner AJ. Membrane protein secretases. Biochem J 1997;321:265-79
- Montana J, Baxter A. The design of selective non-substrate-based matrix metalloproteinase inhibitors. Curr Opin Drug Discov Devel 2000;3:353-61
- Rubino MT, Agamennone M, Campestre C, Synthesis, SAR, and biological evaluation of alpha-sulfonylphosphonic acids as selective matrix metalloproteinase inhibitors. ChemMedChem 2009;4:352-62
- Agrawal A, Romero-Perez D, Jacobsen JA, Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 2008;3:812-20